Our pipeline includes three Core Products: two immunocytokines and one ADCC enhanced mAb. The two immunocytokines, IAP0971 and IAE0972, were developed based on our AIC™ platform. The ADCC enhanced mAb, IAH0968, was developed based on our AEA™ Platform. The following chart summarizes the development status of our Core Products and other selected product candidates as of the Latest Practicable Date.

Overall Strategy of SunHo R&D Pipeline

As of the Latest Practicable Date, we owned 15 issued patents and 123 patent applications, including 53 patent applications in China, nine patent applications in the U.S. and 61 patent applications under the Patent Cooperation Treaty (“PCT"), relating to certain of our product candidates and technologies.